Journal article
Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer
Abstract
9565
Background: Anticoagulant therapy is treatment of choice for cancer-associated thrombosis. However, the risk of symptomatic recurrent thrombosis (RT) is approximately 9% on low molecular weight heparin (LMWH) and 17% on vitamin K antagonist (VKA) therapy, while the risk of anticoagulant-related major bleeding is about 5%. Given such complications are associated with morbidity and increased resource utilization, prognostic …
Authors
Lee A; Parpia S; Julian J; Rickles F; Prins M; Levine M
Journal
Journal of Clinical Oncology, Vol. 27, No. 15_suppl, pp. 9565–9565
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2009
DOI
10.1200/jco.2009.27.15_suppl.9565
ISSN
0732-183X